Veru Inc
Veru Inc logo
VERU

Veru Inc (VERU)

$5.662.75%

Market is closed
– opens on 8 PM, 07 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$5.56
Day's Range
$6.299
$4.34
52-Week Range
$24.55
1 month return60.8%
3 month return50.83%
1 year return10.87%
5 year return466.0%

Company Information

Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111, VERU-100, and Zuclomiphene citrate. VERU-111 is an oral, first-in-class, new chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules for the treatment of metastatic castration and androgen receptor resistant prostate cancer. VERU-100 is a novel, proprietary peptide formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer. Zuclomiphene citrate is an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. The Veru breast cancer pipeline includes enobosarm for AR+/ER+/HER2- metastatic breast cancer and VERU-111 for taxane resistant metastatic triple negative breast cancer. Enobosarm is an oral, first-in-class, new chemical entity, selective androgen receptor agonist that targets and activates the androgen receptor in AR+/ER+/HER2- metastatic breast cancer without unwanted masculinizing side effects. VERU-111 is also being advanced into a Phase 3 trial for the treatment of hospitalized patients with COVID-19 who are at high risk for acute respiratory distress syndrome.
OrganizationVeru Inc
Employees0
CEODr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D.
IndustryConsumer Non-Durables

Analyst Recommendation

based on 5 analysts ratings

Buy
100%
Buy
0%
Hold
0%
Sell

Based on 5 Wall street analysts offering stock ratings for Veru Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 262.19%

Current

$5.66

Target

$20.5

Recommendation Trend

Based on 5 analyst

Current1M Ago3M Ago
Buy
5
10
10
Hold
0
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
453.6M
Book Value
$1.46
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.35
PEG Ratio
0.0
Wall Street Target Price
20.5

Valuation

Trailing PE0.0
Forward PE117.65
Price/Book (mrq)
3.77
Enterprise Value
360.1M
Enterprise Value/Revenue
6.87
Enterprise Value/Ebitda
-8.52

Technicals

Beta
-0.2
50 Day MA
9.75
200 Day MA
11.14

Institutional Holdings

Morgan Stanley - Brokerage Accounts

7.92%

BlackRock Inc

5.31%

Perceptive Advisors LLC

4.86%

Candriam Luxembourg S.C.A.

4.72%

Vanguard Group Inc

3.88%

Boxer Capital LLC

3.12%

Discover more

Frequently Asked Questions

What is Veru Inc share price today?

Can Indians buy Veru Inc shares?

How can I buy Veru Inc shares from India?

Can Fractional shares of Veru Inc be purchased?

What are the documents required to start investing in Veru Inc stocks?

What are today’s High and Low prices of Veru Inc?

What are today’s traded volumes of Veru Inc?

What is today’s market capitalisation of Veru Inc?

What is the 52 Week High and Low Range of Veru Inc?

How much percentage Veru Inc is down from its 52 Week High?

How much percentage Veru Inc is up from its 52 Week low?

What are the historical returns of Veru Inc?

Who is the Chief Executive Officer (CEO) of Veru Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*